LinkMed: Year-end report 2008

LinkMed: Year-end report 2008

GROUP FINANCIAL DEVELOPMENT JULY-DECEMBER
Following the acquisition of 100 percent of the shares of Olerup SSP AB, LinkMed
is now reported as a group.
• Net sales were SEK 35.2 million
• Results from investment activities amounted to SEK 0 million
• Net income after tax was SEK 8.8 million
• Basic earnings per share was SEK 1.00 
• Equity per share was SEK 57.87 
• Equity/assets ratio was 70 percent

PARENT COMPANY FINANCIAL DEVELOPMENT JANUARY-DECEMBER
• Results from investing activities were SEK 0 million (-10.4)
• Other revenue amounted to SEK 3.6 million (5.0)
• Net loss after tax was SEK 13.9 million (- 19.2)

KEY EVENTS IN THE FOURTH QUARTER
• AbSorber is granted its first patent for the transplantation test XM-ONE®
• AbSorber launched XM-ONE® in the U.S.
• AnaMar Medical raises SEK 75 million in new financing
• Ortoviva's Distraktor is granted CE marking and is now in clinical use. 

COMMENTARY ON 2008 FROM CEO INGEMAR LAGERLÖF:
”2008 was an eventful and positive year for LinkMed. The acquisition of Olerup
SSP has given us the opportunity to build a larger company in the
transplantation sector in collaboration with the portfolio company AbSorber.
Following the acquisition, the LinkMed group is showing a profit and is expected
to continue to show a profit before investing activities and a positive
operating cash flow. We have demonstrated that we are successful in building
life science companies in that our portfolio has moved closer to
commercialization. The products of eight of our twelve portfolio companies will
be available on the market in 2009. Even if the life science sector is less
sensitive to the economic climate we see increased cautiousness and longer drawn
out processes with 2009 at hand when it comes to raising capital and exits.”


For more information please contact:
Ingemar Lagerlöf, CEO, cell +46(0)70-873 2733 or e-mail
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell +46(0)70- 600 5364 or e-mail
okee.williams@linkmed.se




LinkMed develops life-science companies in collabora-tion with innovators and
other financiers. By contributing with management competence and capital,
LinkMed has created a portfolio of twelve companies, four in drug development
and biotechnology and eight in diagnostics and medical technology. LinkMed's
role changes in pace with the development of its portfolio companies. The
emphasis moves from operational to strategic and the entrepreneurship role
evolves into active Board work.The company's principal owners are FastPartner,
Koncentra Holding, and the founder Ingemar Lagerlöf. The LinkMed share is listed
on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED).